211 related articles for article (PubMed ID: 24729079)
1. Retinal vascular oximetry during ranibizumab treatment of central retinal vein occlusion.
Traustason S; la Cour M; Larsen M
Br J Ophthalmol; 2014 Sep; 98(9):1208-11. PubMed ID: 24729079
[TBL] [Abstract][Full Text] [Related]
2. Comparison of intravitreal bevacizumab upload followed by a dexamethasone implant versus dexamethasone implant monotherapy for retinal vein occlusion with macular edema.
Mayer WJ; Remy M; Wolf A; Kook D; Kampik A; Ulbig M; Reznicek L; Haritoglou C
Ophthalmologica; 2012; 228(2):110-6. PubMed ID: 22739239
[TBL] [Abstract][Full Text] [Related]
3. Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial.
Brown DM; Wykoff CC; Wong TP; Mariani AF; Croft DE; Schuetzle KL;
Retina; 2014 Sep; 34(9):1728-35. PubMed ID: 24914476
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial.
Priglinger SG; Wolf AH; Kreutzer TC; Kook D; Hofer A; Strauss RW; Alge CS; Kunze C; Haritoglou C; Kampik A
Retina; 2007 Oct; 27(8):1004-12. PubMed ID: 18040236
[TBL] [Abstract][Full Text] [Related]
6. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.
Spaide RF; Chang LK; Klancnik JM; Yannuzzi LA; Sorenson J; Slakter JS; Freund KB; Klein R
Am J Ophthalmol; 2009 Feb; 147(2):298-306. PubMed ID: 18929354
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal ranibizumab for retinal vein occlusion through 1 year in clinical practice.
Brynskov T; Kemp H; Sørensen TL
Retina; 2014 Aug; 34(8):1637-43. PubMed ID: 24646663
[TBL] [Abstract][Full Text] [Related]
8. Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin(®) ).
Algvere PV; Von Wendt G; Gudmundsson J; Seregard S; Kvanta A
Acta Ophthalmol; 2010 Dec; 88(8):836-41. PubMed ID: 19900206
[TBL] [Abstract][Full Text] [Related]
9. Retinal Oxygen Saturation Correlates With Visual Acuity but Does Not Predict Outcome After Anti-VEGF Treatment in Central Retinal Vein Occlusion.
Jeppesen SK; Bek T
Invest Ophthalmol Vis Sci; 2017 May; 58(5):2498-2502. PubMed ID: 28470332
[TBL] [Abstract][Full Text] [Related]
10. Retinal oximetry during treatment of retinal vein occlusion by ranibizumab in patients with high blood pressure and dyslipidemia.
Keilani C; Halalchi A; Wakpi Djeugue D; Regis A; Abada S
J Fr Ophtalmol; 2016 Dec; 39(10):816-821. PubMed ID: 27865689
[TBL] [Abstract][Full Text] [Related]
11. Reading speed improvements in retinal vein occlusion after ranibizumab treatment.
Suñer IJ; Bressler NM; Varma R; Lee P; Dolan CM; Ward J; Colman S; Rubio RG
JAMA Ophthalmol; 2013 Jul; 131(7):851-6. PubMed ID: 23699977
[TBL] [Abstract][Full Text] [Related]
12. Pre-treatment clinical features in central retinal vein occlusion that predict visual outcome following intravitreal ranibizumab.
Brogan K; Precup M; Rodger A; Young D; Gilmour DF
BMC Ophthalmol; 2018 Feb; 18(1):37. PubMed ID: 29426292
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab for treatment of macular edema secondary to central retinal vein occlusion: eighteen-month results of a prospective trial.
Zhang H; Liu ZL; Sun P; Gu F
J Ocul Pharmacol Ther; 2011 Dec; 27(6):615-21. PubMed ID: 21823986
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal ranibizumab for macular edema secondary to retinal vein occlusion.
Kim M; Yu SY; Kim ES; Bae SH; Park JH; Yu HG; Kwak HW
Ophthalmologica; 2012; 227(3):132-8. PubMed ID: 22212151
[TBL] [Abstract][Full Text] [Related]
15. Results of bevacizumab as the primary treatment for retinal vein occlusions.
Figueroa MS; Contreras I; Noval S; Arruabarrena C
Br J Ophthalmol; 2010 Aug; 94(8):1052-6. PubMed ID: 20679089
[TBL] [Abstract][Full Text] [Related]
16. Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials.
Thach AB; Yau L; Hoang C; Tuomi L
Ophthalmology; 2014 May; 121(5):1059-66. PubMed ID: 24424249
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal ranibizumab (Lucentis) for treatment of central retinal vein occlusion: a prospective study.
Rouvas A; Petrou P; Vergados I; Pechtasides D; Liarakos V; Mitsopoulou M; Ladas I
Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1609-16. PubMed ID: 19609550
[TBL] [Abstract][Full Text] [Related]
18. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study.
Epstein DL; Algvere PV; von Wendt G; Seregard S; Kvanta A
Ophthalmology; 2012 Jun; 119(6):1184-9. PubMed ID: 22424833
[TBL] [Abstract][Full Text] [Related]
20. Impact of Intravitreal Ranibizumab on Vessel Functionality in Patients With Retinal Vein Occlusion.
Corvi F; La Spina C; Benatti L; Querques L; Lattanzio R; Bandello F; Querques G
Am J Ophthalmol; 2015 Jul; 160(1):45-52.e1. PubMed ID: 25896458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
